iTWire - Biotech Esfam says on-track to start human trials for a COVID-19 treatment by end of 2021 itwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itwire.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Tau accumulation over one year measured in composite A) mesial temporal ROI; and B) temporoparietal ROI in cognitively unimpaired participants (blue) and cognitively impaired participants (red). The CI group included. view more
Credit: Image created by N Krishnadas et al. Florey Department of Neurosciences & Mental Health, The University of Melbourne; Department of Molecular Imaging & Therapy, Austin Hospital, Melbourne.
Reston, VA (Embargoed until 7:30 p.m. EDT, Monday, June 14, 2021) A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau a distinguishing characteristic of Alzheimer s disease before any symptoms of the disease are observed. With the potential to measure increases in tau over a long period of time, this tracer offers an important tool to assess the effectiveness of Alzheimer s disease treatments in clinical trials. This research was presented at the Society of Nuclear Medicine
The researchers said the tests show the vaccine was safe to use and produced an immune response, but cautioned that more testing is necessary.
PET scan of a human brain with Alzheimer’s disease. (Photo by US National Institute on Aging, Alzheimer’s Disease Education and Referral Center)
(CN) Alzheimer’s disease is one of the leading causes of death in the U.S. but the results of a new breakthrough vaccine announced Monday shows promise in the effort to curb the deadly brain disorder.
Biotech company Axon Neuroscience released the results of its Phase II testing of its vaccine in the journal Nature Aging. The two-year trial, involving 196 patients from eight European countries, was demonstrated to be safe and effective with those suffering from mild Alzheimer’s disease.
Healthcare sources say hospitals have been unable to secure casual workers as most have taken up work on the more lucrative COVID-19 testing and vaccination programs.